250 related articles for article (PubMed ID: 30302023)
1. The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
Kha ML; Hesse L; Deisinger F; Sipos B; Röcken C; Arlt A; Sebens S; Helm O; Schäfer H
Oncogene; 2019 Feb; 38(9):1461-1476. PubMed ID: 30302023
[TBL] [Abstract][Full Text] [Related]
2. The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1.
Genrich G; Kruppa M; Lenk L; Helm O; Broich A; Freitag-Wolf S; Röcken C; Sipos B; Schäfer H; Sebens S
BMC Cancer; 2016 Feb; 16():155. PubMed ID: 26915435
[TBL] [Abstract][Full Text] [Related]
3. The Crosstalk between Nrf2 and TGF-β1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells.
Arfmann-Knübel S; Struck B; Genrich G; Helm O; Sipos B; Sebens S; Schäfer H
PLoS One; 2015; 10(7):e0132978. PubMed ID: 26226105
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer.
Geismann C; Morscheck M; Koch D; Bergmann F; Ungefroren H; Arlt A; Tsao MS; Bachem MG; Altevogt P; Sipos B; Fölsch UR; Schäfer H; Müerköster SS
Cancer Res; 2009 May; 69(10):4517-26. PubMed ID: 19435915
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
6. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases.
Müerköster SS; Werbing V; Koch D; Sipos B; Ammerpohl O; Kalthoff H; Tsao MS; Fölsch UR; Schäfer H
Int J Cancer; 2008 Oct; 123(8):1751-60. PubMed ID: 18649362
[TBL] [Abstract][Full Text] [Related]
7. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
8. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-β1 (TGF-β)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells.
Geismann C; Arlt A; Bauer I; Pfeifer M; Schirmer U; Altevogt P; Müerköster SS; Schäfer H
Int J Oncol; 2011 Jan; 38(1):257-66. PubMed ID: 21109948
[TBL] [Abstract][Full Text] [Related]
9. Rac1b negatively regulates TGF-β1-induced cell motility in pancreatic ductal epithelial cells by suppressing Smad signalling.
Ungefroren H; Sebens S; Giehl K; Helm O; Groth S; Fändrich F; Röcken C; Sipos B; Lehnert H; Gieseler F
Oncotarget; 2014 Jan; 5(1):277-90. PubMed ID: 24378395
[TBL] [Abstract][Full Text] [Related]
10. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Jagadeeshan S; Subramanian A; Tentu S; Beesetti S; Singhal M; Raghavan S; Surabhi RP; Mavuluri J; Bhoopalan H; Biswal J; Pitani RS; Chidambaram S; Sundaram S; Malathi R; Jeyaraman J; Nair AS; Venkatraman G; Rayala SK
Ann Oncol; 2016 Aug; 27(8):1546-56. PubMed ID: 27117533
[TBL] [Abstract][Full Text] [Related]
11. Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells.
Rahn S; Zimmermann V; Viol F; Knaack H; Stemmer K; Peters L; Lenk L; Ungefroren H; Saur D; Schäfer H; Helm O; Sebens S
Cancer Lett; 2018 Feb; 415():129-150. PubMed ID: 29222037
[TBL] [Abstract][Full Text] [Related]
12. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
13. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Zhang D; Li L; Jiang H; Knolhoff BL; Lockhart AC; Wang-Gillam A; DeNardo DG; Ruzinova MB; Lim KH
Clin Cancer Res; 2017 Apr; 23(7):1748-1759. PubMed ID: 27702822
[No Abstract] [Full Text] [Related]
14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
15. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Xiong G; Huang H; Feng M; Yang G; Zheng S; You L; Zheng L; Hu Y; Zhang T; Zhao Y
J Exp Clin Cancer Res; 2018 Apr; 37(1):76. PubMed ID: 29615098
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
[TBL] [Abstract][Full Text] [Related]
17. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
Ju HQ; Gocho T; Aguilar M; Wu M; Zhuang ZN; Fu J; Yanaga K; Huang P; Chiao PJ
Mol Cancer Ther; 2015 Mar; 14(3):788-98. PubMed ID: 25527634
[TBL] [Abstract][Full Text] [Related]
20. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
